News
COGZF
0.940
NaN%
--
Weekly Report: what happened at COGZF last week (0609-0613)?
Weekly Report · 5d ago
Cogstate Launches InvestorHub to Boost Engagement and Drive CNS Research Innovation
TipRanks · 06/12 23:09
Increase in Substantial Shareholder’s Voting Power at Cogstate Limited
TipRanks · 06/11 01:18
Weekly Report: what happened at COGZF last week (0602-0606)?
Weekly Report · 06/09 10:51
Canaccord Genuity Sticks to Their Buy Rating for Cogstate Ltd (COGZF)
TipRanks · 06/05 07:05
Weekly Report: what happened at COGZF last week (0526-0530)?
Weekly Report · 06/02 10:58
Weekly Report: what happened at COGZF last week (0519-0523)?
Weekly Report · 05/26 10:57
Cogstate Announces Retirement of Long-Standing Non-Executive Director
TipRanks · 05/20 23:07
Weekly Report: what happened at COGZF last week (0512-0516)?
Weekly Report · 05/19 10:50
Weekly Report: what happened at COGZF last week (0505-0509)?
Weekly Report · 05/12 10:50
Cogstate Ltd Updates on Buy-Back Program
TipRanks · 05/08 23:27
Cogstate Ltd Updates on Market Buy-Back Program
TipRanks · 05/07 22:46
Cogstate Ltd Updates on Buy-Back Program
TipRanks · 05/06 22:58
Weekly Report: what happened at COGZF last week (0428-0502)?
Weekly Report · 05/05 10:52
Cogstate Ltd Updates on Share Buy-Back Progress
TipRanks · 05/04 23:18
Cogstate Ltd Updates on Ongoing Share Buy-Back Program
TipRanks · 05/01 23:08
Cogstate Ltd Updates on Share Buy-Back Progress
TipRanks · 04/30 23:18
Cogstate Ltd Expands Securities Offering on ASX
TipRanks · 04/30 04:38
Cogstate Ltd Updates on Market Buy-Back Progress
TipRanks · 04/28 23:37
Weekly Report: what happened at COGZF last week (0421-0425)?
Weekly Report · 04/28 10:59
More
Webull provides a variety of real-time COGZF stock news. You can receive the latest news about Cogstate through multiple platforms. This information may help you make smarter investment decisions.
About COGZF
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.